Exacerbation frequency strongly influences treatment choices in patients with severe asthma. What is the extent of the variability of exacerbations rate across countries and its implications in disease management? We retrieved data from the International Severe Asthma Registry, an international observational cohort of patients with a clinical diagnosis of severe asthma. We identified patients aged ≥18 years who did not initiate any biologics prior to baseline visit. A severe exacerbation was defined as the use of oral corticosteroids for ≥3 days or asthma-related hospitalization/emergency room visit. A series of negative binomial models were applied to estimate country-specific severe exacerbation rates during 365 days of follow-up, starting from a naïve model with country as the only variable, to an adjusted model with country as a random-effect term and patient and disease characteristics as independent variables. The final sample included 7,510 patients from 17 countries (56% from the United States), contributing to 1,939 severe exacerbations (0.27/person-year). There was large between-country variation in observed severe exacerbation rate (min: 0.04 [Argentina], max:0.88 [Saudi Arabia], interquartile range [IQR]: 0.13-0.54), which remained substantial after adjusting for patient characteristics and sampling variability (IQR: 0.16-0.39). Individuals with similar patient characteristics but coming from different jurisdictions have varied severe exacerbation risks, even after controlling for patient and disease characteristics. This suggests unknown patient factors or system-level variations at play. Disease management guidelines should recognize such between-country variability. Risk prediction models that are calibrated for each jurisdiction will be needed to optimize treatment strategies. N/A.
Accurate risk prediction of exacerbations is pivotal in severe asthma management. Multiple risk factors are at play, but the pathway of risk prediction remains unclear. How do the interplays of clinically relevant predictors lead to severe exacerbations in patients with severe asthma? Severe asthma patients (N=6814, ≥18 years), biologic naïve, were identified from the Severe Asthma Registry (2017-2021). Relevant predictors covered demographics, lung function, inflammation biomarkers, healthcare utilization, medications, exacerbation history, and comorbidities. Bayesian network (BN), representing the prediction process of severe exacerbations, was obtained by combining expert knowledge and machine learning algorithms. Internal validation was performed. The proposed influence diagram integrated decision and utility nodes into the prediction pathway. The BN analysis revealed that blood eosinophil count (BEC), fractional exhaled nitric oxide (FeNO) level, and % predicted forced expiratory volume in 1 second (FEV1) directly influenced the transition between prior and future severe exacerbations. The presence of chronic rhinosinusitis (CRS) indirectly affected such transition by directly influencing BEC, FeNO, and % predicted FEV1. Macrolide use independently affected history of exacerbations to influence future severe asthma exacerbations. Model discrimination was moderate in 10-fold cross-validation and leave-one-country-out cross-validation, and model calibration was high in train-test data. An essential prediction pathway of severe exacerbation was identified, which involves the influence of CRS on the immediate predictors of risk transition from current to future severe asthma exacerbations. Macrolide use was another essential prediction pathway. The findings support shared clinical decision-making in severe asthma treatment. N/A.
Background: Accurate risk prediction of exacerbations in asthma patients promotes personalized asthma management. Objective: This systematic review aimed to provide an update and critically appraise the quality and usability of asthma exacerbation prediction models which were developed since 2017. Methods: In the Embase and PubMed databases, we performed a systematic search for studies published in English between May 2017 and August 2023, and identified peer-reviewed publications regarding the development of prognostic prediction models for the risk of asthma exacerbations in adult patients with asthma. We then applied the Prediction Risk of Bias Assessment tool (PROBAST) to assess the risk of bias and applicability of the included models. Results: Of 415 studies screened, 10 met eligibility criteria, comprising 41 prediction models. Among them, 7 (70%) studies used real-world data (RWD) and 3 (30%) were based on trial data to derive the models, 7 (70%) studies applied machine learning algorithms, and 2 (20%) studies included biomarkers like blood eosinophil count and fractional exhaled nitric oxide in the model. PROBAST indicated a generally high risk of bias (80%) in these models, which mainly originated from the sample selection (“Participant” domain, 6 studies) and statistical analysis (“Analysis” domain, 7 studies). Meanwhile, 5 (50%) studies were rated as having a high concern in applicability due to model complexity. Conclusion: Despite the use of big health data and advanced ML, asthma risk prediction models from 2017– 2023 had high risk of bias and limited practical use. Future efforts should enhance generalizability and practicality for real-world implementation.
10 March 2025 in Nucleosides, Nucleotides & Nucleic Acids
Epigenetic modifications play a crucial role in various diseases, including cancer. Targeting chromatin modulators to normalize these epigenetic markers is a promising avenue for overcoming cancer drug resistance and improving treatment efficacy. Histone chaperones, implicated in cancer due to their imperfect compensatory mechanisms, represent potential targets for epidrugs. To identify these targets, we performed enrichment and network analyses of histone chaperone interactions, both among themselves and with other proteins. This approach provided insights into structure-function relationships. The selective binding of histone chaperones to canonical histones highlights their potential as epidrugs targets. Network analysis of common histone chaperones identified key hub proteins: HSP90AB1, RBBP4, NPM1, DAXX, and SET. These hub proteins, particularly RBBP4, which formed the largest protein cluster was found associated with oncogenesis, suggesting RBBP4 as prime candidates for therapeutic intervention. Druggability prediction of these hub protein pockets further identified RBBP4 as the most promising target, with Ritonavir emerging as a potential epidrugs. These findings provide a crucial foundation for future epidrugs discovery targeting cancer.
4 October 2024 in Life Cycle Reliability and Safety Engineering
In many cross-sectional studies, the chances that an individual will be able to exactly recall the event are very low. The possibility of recalling the exact time as well as the cause of occurrence of an event usually decreases as the gap between event and monitoring time increases. This gives rise to non-recall current status data. In this article, an efficient approach to deal with such non-recall current status data is established in a competing risk set up. In the classical method, a nested Expectation–Maximization technique is worked out for the estimation purpose and the information matrix is evaluated using the missing information principle. In the Bayesian paradigm, point and interval estimates are obtained using the Gibbs sampling algorithm. A recent anthropometric study data containing the menarcheal status of girls and age at menarche is analyzed using the considered methodology.